Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

VK2735 to Advance to Phase 3 for Obesity; End-of-Phase 2 Meeting Planned for 2H24 Enrollment Completed in Phase 1b Study of VK0214 for X-ALD; Data Expected 2H24 "The first half of 2024 was marked by strong momentum in the company's pipeline programs, as we reported successful outcomes from three different clinical trials, and began preparing for next steps with each program," stated Brian Lian, Ph.D., chief executive officer of Viking. "The Phase 2 VENTURE study of VK2735 in obesity demonstrated up to an ap ...